{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:05:35Z","timestamp":1790067935728,"version":"4.0.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Thromboembolic complications remain among the most serious complications of childhood idiopathic nephrotic syndrome (INS). Although their incidence is considerably lower than in adults, venous thromboembolism continues to cause substantial morbidity and occasional mortality, including pulmonary embolism, cerebral venous sinus thrombosis, and extensive deep venous thrombosis. Preventive management remains controversial because most affected children may not develop thrombosis, whereas pharmacological prophylaxis exposes many low-risk patients to potential overtreatment. Current recommendations are largely based on retrospective studies, expert opinions, and extrapolation from adult nephrotic syndrome, while prospective pediatric evidence remains scarce. This review examines the contemporary understanding of thrombogenesis in childhood INS, emphasizing that hypercoagulability extends beyond urinary antithrombin loss to involve hepatic overproduction of procoagulant factors, impaired fibrinolysis, platelet activation, endothelial dysfunction, and hemoconcentration. We also discuss the possibility that historical thrombotic risk may have been amplified by prolonged corticosteroid exposure and consider whether the widespread adoption of steroid-sparing immunosuppressive therapies and earlier relapse detection may have modified the epidemiology of thromboembolism in the modern therapeutic era. Current preventive strategies\u2014including no routine prophylaxis, biomarker-guided individualized approaches, aspirin, and prophylactic low-molecular-weight heparin (LMWH)\u2014are critically reviewed. We argue that increasingly complex biomarker-based algorithms have not demonstrated clear clinical superiority over simple, pragmatic decision-making. Severe hypoalbuminemia provides a pragmatic surrogate of nephrotic severity and may therefore help identify children in whom the overall prothrombotic state is likely to be substantial. We are not proposing albumin &amp;lt;20\u2005g\/L as a validated predictor of thrombosis. We are proposing it as a pragmatic clinical trigger for considering prophylaxis in a disease in which no validated predictive model currently exists. We propose a pragmatic risk-stratified approach in which routine pharmacological prophylaxis is unnecessary for early biochemical relapses with minimal clinical manifestations but should be strongly considered in children and adolescents with clinically significant active nephrotic syndrome associated with severe hypoalbuminemia (approximately &amp;lt;20\u2005g\/L), provided no major contraindications exist. Where feasible, LMWH appears to be the most appropriate prophylactic agent. Until prospective pediatric studies better define thrombotic risk and validate prediction models, practical consistency based on clinically meaningful risk thresholds may provide a more rational framework than theoretical precision for thromboprophylaxis in childhood INS.<\/jats:p>","DOI":"10.3389\/fped.2026.1933209","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:48:17Z","timestamp":1790066897000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Thromboembolic prophylaxis in childhood idiopathic nephrotic syndrome. From pathophysiology to clinical management"],"prefix":"10.3389","volume":"14","author":[{"given":"Tim","family":"Ulinski","sequence":"first","affiliation":[{"name":"Pediatric Nephrology Department, Trousseau Hospital, AP-HP.Sorbonne Universit\u00e9","place":["Paris, France"]},{"name":"Faculty of Medicine, Sorbonne Universit\u00e9","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Aoun","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Department, Trousseau Hospital, AP-HP.Sorbonne Universit\u00e9","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00467-013-2525-5","article-title":"Venous thromboembolism in pediatric nephrotic syndrome","volume":"29","author":"Kerlin","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10157-013-0917-2","article-title":"Thromboembolic complications in childhood nephrotic syndrome: a clinical profile","volume":"18","author":"Suri","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00467-003-1281-3","article-title":"Mesenteric thrombosis causing short bowel syndrome in nephrotic syndrome","volume":"18","author":"Ulinski","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12882-023-03160-y","article-title":"Incidence of thromboembolism in children with primary nephrotic syndrome: a systematic review and metaanalysis","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Nephrol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1207871","DOI":"10.3389\/fped.2023.1207871","article-title":"Cerebral sinovenous thrombosis in children with nephrotic syndrome: systematic review and one new case","volume":"11","author":"Konop\u00e1sek","year":"2023","journal-title":"Front Pediatr"},{"key":"B7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ki.1985.149","article-title":"Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome","volume":"28","author":"Llach","year":"1985","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(23)01051-6","article-title":"Childhood nephrotic syndrome","volume":"402","author":"Vivarelli","year":"2023","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s004670050029","article-title":"Hemostatic problems and thromboembolic complications in nephrotic children","volume":"14","author":"Citak","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/s0022-3476(87)80397-9","article-title":"Hemostasis and thromboembolism in children with nephrotic syndrome: differences from adults","volume":"110","author":"Mehls","year":"1987","journal-title":"J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2215\/CJN.0000000000000047","article-title":"Exploring the role of antithrombin in nephrotic syndrome-associated hypercoagulopathy: a multi-cohort study and meta-analysis","volume":"18","author":"Abdelghani","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1056\/NEJMcibr1209459","article-title":"Venous thrombosis in the nephrotic syndrome","volume":"368","author":"Loscalzo","year":"2013","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.thromres.2005.03.030","article-title":"Thromboembolic complications in the nephrotic syndrome: pathophysiology and clinical management","volume":"118","author":"Singhal","year":"2006","journal-title":"Thromb Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21802\/artm.2026.2.38.55","article-title":"Natural anticoagulant deficiencies in patients with nephrotic syndrome: comparative evaluation of antithrombin iii, protein C and protein S and their association with hypercoagulability markers","volume":"38","author":"Mykhaloiko","year":"2026","journal-title":"Sci Pract J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2174\/157016111203140518172048","article-title":"Hypercoagulability and nephrotic syndrome","volume":"12","author":"Gigante","year":"2014","journal-title":"CVP"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.34067\/KID.0000000865","article-title":"Alterations in coagulation and endothelial function in nephrotic syndrome: a multicenter, cross-sectional analysis","volume":"6","author":"Kelddal","year":"2025","journal-title":"Kidney360"},{"key":"B17","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/j.1538-7836.2010.04034.x","article-title":"Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors","volume":"8","author":"Van Zaane","year":"2010","journal-title":"JThromb Haemost"},{"key":"B19","doi-asserted-by":"publisher","first-page":"sfaf381","DOI":"10.1093\/ckj\/sfaf381","article-title":"The 2025 KDIGO guideline on the management of nephrotic syndrome in children: a comment of the European renal association immunonephrology working group","volume":"19","author":"Frangou","year":"2026","journal-title":"Clin Kidney J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e14544","DOI":"10.1111\/petr.14544","article-title":"Successful global anti-B-cell strategy with daratumumab in a patient with post-transplant nephrotic syndrome recurrence unresponsive to immunoadsorption and obinutuzumab","volume":"27","author":"Delbet","year":"2023","journal-title":"Pediatr Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","article-title":"Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children","volume":"18","author":"Dossier","year":"2023","journal-title":"CJASN"},{"key":"B23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00467-018-4149-2","article-title":"Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study","volume":"34","author":"Dossier","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00467-017-3746-9","article-title":"Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials","volume":"33","author":"Iijima","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2215\/CJN.08500815","article-title":"Anti-CD20 antibodies for idiopathic nephrotic syndrome in children","volume":"11","author":"Ravani","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ejpn.2019.02.007","article-title":"Neurological complications in childhood nephrotic syndrome: a systematic review","volume":"23","author":"Stabouli","year":"2019","journal-title":"Eur J Paediatr Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","article-title":"IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome","volume":"38","author":"Trautmann","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s004310050972","article-title":"Inherited risk factors for thrombophilia in children with nephrotic syndrome","volume":"157","author":"Fabri","year":"1998","journal-title":"Euro J Pediatr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fped.2017.00050","article-title":"Inherited thrombophilia in pediatric venous thromboembolic disease: why and who to test","volume":"5","author":"Van Ommen","year":"2017","journal-title":"Front Pediatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1538-7836.2009.03572.x","article-title":"Clinical probability score and D-dimer estimation lack utility in the diagnosis of childhood pulmonary embolism","volume":"7","author":"Biss","year":"2009","journal-title":"J Thromb Haemost"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1038\/s41390-022-02302-6","article-title":"Childhood nephrotic syndrome and the clinical profile of thromboembolism: a systematic review and meta-analysis","volume":"93","author":"Dadgar","year":"2023","journal-title":"Pediatr Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14779072.2020.1823218","article-title":"Rivaroxaban for the treatment of venous thromboembolism in pediatric patients","volume":"18","author":"Cohen","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1933209\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:48:18Z","timestamp":1790066898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1933209\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":35,"alternative-id":["10.3389\/fped.2026.1933209"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1933209","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1933209"}}